{"disease":{"id":"respiratory-syncytial-virus","name":"respiratory syncytial virus"},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV-associated hospitalization due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in young children with a history of premature birth or bronchopulmonary dysplasia.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"rsv-prefusion-f-protein-based-vaccine","indication_name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSV prefusion F protein-based vaccine","generic_name":"rsv-prefusion-f-protein-based-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Respiratory syncytial virus fusion (F) protein","drug_class":"Viral protein subunit vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ribavarin","indication_name":"Respiratory syncytial virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"active","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Active","generic_name":"active","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Sisunatovir","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rv521","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RV521","generic_name":"rv521","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"RV521 drug in capsules","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sisunatovir","indication_name":"Respiratory Syncytial Virus Infection","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sisunatovir","generic_name":"sisunatovir","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Participants will receive tablets from Day 1 to Day 5","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":10,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT05622331","title":"Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden","phase":"","overall_status":"COMPLETED","enrollment_count":1100000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06325332","title":"BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)","phase":"","overall_status":"COMPLETED","enrollment_count":49680,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07249320","title":"Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39456,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05127434","title":"A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":36814,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT01155193","title":"Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":30804,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":true},{"nct_id":"NCT04886596","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26675,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04908683","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25236,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT07272434","title":"Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"MAXVAX Biotechnology Limited Liability Company","has_results":false},{"nct_id":"NCT05238025","title":"MVA-BN-RSV Vaccine Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":20419,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT06207929","title":"Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections","phase":"","overall_status":"COMPLETED","enrollment_count":18157,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT06229444","title":"Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI","phase":"NA","overall_status":"COMPLETED","enrollment_count":17043,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT04605159","title":"A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":11194,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05572658","title":"Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study","phase":"","overall_status":"COMPLETED","enrollment_count":10994,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06534892","title":"An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10212,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04623047","title":"Infection Watch Study","phase":"","overall_status":"COMPLETED","enrollment_count":10034,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT03627572","title":"RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT03982199","title":"A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5815,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT06251024","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4541,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03614676","title":"A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance","phase":"NA","overall_status":"COMPLETED","enrollment_count":4493,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07346963","title":"RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Eskisehir Osmangazi University","has_results":false},{"nct_id":"NCT05705440","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3855,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04767373","title":"Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":3632,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05330975","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3317,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT03979313","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3012,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04959734","title":"COVID-19 Impact on RSV Emergency Presentations","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University Hospitals, Leicester","has_results":false},{"nct_id":"NCT07200206","title":"A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06551181","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2621,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01995175","title":"A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age","phase":"NA","overall_status":"COMPLETED","enrollment_count":2409,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06824207","title":"Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07177508","title":"First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2355,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06083623","title":"A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":2282,"lead_sponsor_name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05242432","title":"A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2192,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":false},{"nct_id":"NCT06521944","title":"RSV Vaccine Pregnancy Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2062,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT03698084","title":"RESCEU: Defining the Burden of RSV Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04288921","title":"Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT02508194","title":"A Study to Evaluate the Efficacy of MEDI7510 in Older Adults","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1900,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT06060457","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1900,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT04732871","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1720,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05045144","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1586,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05590403","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1544,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06686654","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1530,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05301322","title":"Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1471,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06389487","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1459,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02878330","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1453,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT00246480","title":"RSV Disease in the Elderly","phase":"","overall_status":"COMPLETED","enrollment_count":1401,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}